Susan Altschuller
Director of Finance/CFO at CEREVEL THERAPEUTICS HOLDINGS, INC.
Net worth: 693 433 $ as of 2024-02-28
Profile
Susan Altschuller holds the position of Chief Financial Officer for Cerevel Therapeutics Holdings, Inc. and Chief Financial Officer for Cerevel Therapeutics, Inc. (a subsidiary of Cerevel Therapeutics Holdings, Inc.).
She is also on the board of Vestaron Corp.
and Mural Oncology Plc and Founding Member at HNRNP Family Foundation.
She previously occupied the position of Chief Financial Officer & Senior Vice President at ImmunoGen, Inc., Head-Investor Relations for Biogen, Inc., Vice President-Investor Relations for Alexion Pharmaceuticals, Inc. and Head-Investor Relations at Bioverativ, Inc.
She received an undergraduate degree from Tulane University (Louisiana), a doctorate from Illinois Institute of Technology and an MBA from MIT Sloan School of Management.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-01-18 | 16,913 ( 0.01% ) | 693 433 $ | 2024-02-28 |
Susan Altschuller active positions
Companies | Position | Start |
---|---|---|
CEREVEL THERAPEUTICS HOLDINGS, INC. | Director of Finance/CFO | 2023-05-14 |
Vestaron Corp.
Vestaron Corp. Chemicals: SpecialtyProcess Industries Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC. | Director/Board Member | - |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Director of Finance/CFO | 2023-04-30 |
Former positions of Susan Altschuller
Companies | Position | End |
---|---|---|
IMMUNOGEN, INC. | Director of Finance/CFO | 2022-12-22 |
ALEXION PHARMACEUTICALS, INC. | Investor Relations Contact | 2020-06-30 |
BIOVERATIV INC | Public Communications Contact | - |
BIOGEN INC. | Investor Relations Contact | - |
Training of Susan Altschuller
Illinois Institute of Technology | Doctorate Degree |
Tulane University (Louisiana) | Undergraduate Degree |
MIT Sloan School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
IMMUNOGEN, INC. | Health Technology |
BIOGEN INC. | Health Technology |
CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
Private companies | 4 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Vestaron Corp.
Vestaron Corp. Chemicals: SpecialtyProcess Industries Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC. | Process Industries |
Bioverativ, Inc.
Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Health Technology |